New drug trial aims to soothe painful skin rash for cancer patients

NCT ID NCT04697069

Summary

This study tested a drug called imsidolimab to see if it could reduce a painful, acne-like skin rash that is a common side effect of certain cancer treatments. It involved a small group of cancer patients who developed this rash while taking specific targeted therapies. The goal was to see if the drug could safely reduce the number of skin bumps, ease itching and pain, and improve patients' quality of life.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACNEIFORM ERUPTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Site 101

    St Louis, Missouri, 63110, United States

  • Site 102

    Tampa, Florida, 33620, United States

  • Site 103

    Houston, Texas, 77030, United States

  • Site 105

    Columbus, Ohio, 43215, United States

  • Site 106

    Boston, Massachusetts, 02215, United States

  • Site 201

    Szczecin, 70-784, Poland

  • Site 203

    Poznan, 60-569, Poland

  • Site 204

    Gliwice, 44-102, Poland

  • Site 301

    Olomouc, 779 00, Czechia

  • Site 302

    New Town, Praha 2, 128 00, Czechia

  • Site 303

    Brno, 656-91, Czechia

  • Site 304

    Plzen-Bory, 305 99, Czechia

  • Site 401

    Tbilisi, 0186, Georgia

  • Site 402

    Tbilisi, 0144, Georgia

  • Site 403

    Tbilisi, 0160, Georgia

  • Site 404

    Batumi, 6000, Georgia

  • Site 405

    Tbilisi, 0160, Georgia

  • Site 601

    Riga, 1038, Latvia

Conditions

Explore the condition pages connected to this study.